Address
2500 Faber Pl
Palo Alto, CA 94303
Introducing New VirusHunter™ Assays
SARS-CoV-2 whole genome sequencing on QuadCore™ chips
Fast Detection of SARS-CoV-2 and Influneza A/B on ATOM™ chips
ATOM™ Chips
Little Chips, Big Impact
ATOM™ chips are available as 8, 24, 48, 96, or 384 chips packaged on 384-well plates for ease of use. Each 1mm x 1mm chip contains sequences for the detection of 56 pathogens, 16 antibiotic resistance genes, and 6 controls. Assays using these chips can be customized to suit your needs.
The VirusHunter™ MVP assay is an RT-PCR based assay with incredibly high sensitivity for the detection of SARS-CoV-2 and Influenza A and B on ATOM™ chips. Check out our resources below for more information.
Clinically Validated
The MVP assay has been submitted to the FDA for Emergency use Authorization. 50 positive and 51 negative patient samples were evaluated with both the MVP assay and qPCR. 100% agreement was observed.
95% Confidence Intervals | |||
Value | Lower Limit | Upper Limit | |
Sensitivity | 100% | 92.89% | 100.0% |
Specificity | 100% | 93.02% | 100.0% |
Positive Agreement PPA | 100% | 96.41% | 100.0% |
Negative Agreement PNA | 100% | 96.41% | 100.0% |
Overall Agreement POA | 100% | 96.41% | 100.0% |
Highest Sensitivity Testing
ATOM™ chips contain 8 probes for base queried in the MVP assay as opposed to traditional RT-PCR, which uses one probe per target. This makes the chip and incredibly sensitive method of detection in comparison.
The detection limits for the MVP assay using a 200µL pre-extraction volume and a 50µL elution volume are:
- SARS-CoV-2: 125 copies per mL (5 copies per reaction)
- Influenza B (Phuket/3073/13): 0.01 TCID50/mL
- Influenza B (Colorado/6/17): 005 TCID50/mL
- Influenza A H3N2 (Kansas/14/17):05 TCID50/mL
- Influenza A H1N1 (Brisbane/59/07):01 TCID50/mL
QuadCore™ Chips
Flexible, Accurate Sequencing
QuadCorechips are available as 8, 24, 48, or 98 chips packaged on 384-well plates to suit your needs. The VirusHunter™ ARTIC SARS-CoV-2 Whole Genome Sequencing Assay uses a multiplex tiling RT-PCR reaction originally developed by the ARTIC Network. These RT-PCR products are read out on QuadCore™ DNA sequencing chips with astounding accuracy. Core 0 of the QuadCore™ chip contains eight probes for each base in the SARS-CoV-2 genome; four probes (A, T, C, and G) on the sense strand, and four probes on the antisense strand. Cores 1-3 contain SARS-CoV-2 variant sequences and control sequences.
Easy to Use
Go from sample to sequence in under 24 hours with the VirusHunter™ ARTIC SARS-CoV-2 Whole Genome Sequencing Assay. Complete the sequencing workflow in six simple steps:
RT-PCR (4 hours)
Fragmentation (45 minutes)
Hybridization (one hour or overnight)
Staining (30 minutes)
Scanning (8 minutes per chip)
Data Processing (3 minutes per chip)
Simple Output for Variant Tracking
Rapidly uncover important epidemiological and phylogenetic data with the VirusHunter™ variant calling output. The variant output file is automatically generated using VirusHunter™ software. It enables rapid sequence analysis and strain or clade determination using published variant data. Whole genome FASTA and FASTQ files are output at the same time to enable deeper sequencing analysis using custom pipelines.
The VirusHunter™ MVP assay is currently only available through our clinical lab, Molecular Vision laboratories. Visit their site by clicking here.
Click for More Info:
Product Sheet: VirusHunter™ MVP Assay
SARS-CoV-2 and Influenza Detection on ATOM™ chips
Product Sheet: VirusHunter™ ARTIC Sequencing Assay
Whole genome sequencing on QuadCore™ chips
Product Overview and Launch Announcement
VirusHunter™ Assays for QuadCore™ and ATOM™
Recent Publication: ARTIC Sequencing
Highly Accurate Chip-Based Resequencing of SARS-CoV-2 Clinical Samples
Recent Publication: ARTIC Sequencing
SARS-CoV-2 Variant Identification Using a Genome Tiling Array and Genotyping Probes
“Since the submission of the paper, the technology has further evolved with improved accuracy and sensitivity. The QuadCore sequencing technology is the best available technology for a large scale viral genome surveillance and monitoring viral variants. This could not only help control this pandemic and also prevent future pandemics.”
Professor and Director, Center for Biomedical Engineering,
Director of Bioinformatics, Comprehensive Cancer Center, University of New Mexico